Expanded collaboration grants Alamar commercial rights to utilize ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests for clinical use CARLSBAD, Calif., July 23, 2026 /PRNewswire/ — ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
